GlassScriptPhysician profile
Rajini Manjunath
NPI 1043207251
$3,454.98
in general payments reported to CMS, 2019-2025
31 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $93.08 · 2021: $223 · 2022: $584 · 2023: $788 · 2024: $659 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.99 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $683.85 | 2019-2025 | |
| Gilead Sciences, INC. | $358.90 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $338.10 | 2019-2024 | Opdivo, Opdualag |
| Abbvie INC. | $332.88 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $188.81 | 2020-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $175.37 | 2022-2025 | Pomalyst, Reblozyl |
| Janssen Pharmaceuticals, INC | $163.78 | 2019-2020 | |
| Pfizer INC. | $150.52 | 2019-2025 | |
| Astellas Pharma US INC | $146.47 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Merck Sharp & Dohme LLC | $111.69 | 2019-2025 | Keytruda |
| Glaxosmithkline, LLC. | $96.31 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Seagen INC. | $84.99 | 2023 | |
| Array Biopharma INC | $61.77 | 2022-2025 | Lorbrena |
| Daiichi Sankyo INC. | $60.00 | 2024-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $56.86 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $47.49 | 2022-2023 | Vonjo |
| Blueprint Medicines Corporation | $45.09 | 2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $42.53 | 2023-2025 | |
| Tempus Ai, INC | $35.72 | 2024 | |
| Genzyme Corporation | $33.58 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $30.12 | 2022 | |
| Pharmaessentia USA Corporation | $28.37 | 2025 | Besremi |
| Alnylam Pharmaceuticals INC. | $28.21 | 2023 | Givlaari |
| Agios Pharmaceuticals, INC. | $26.14 | 2024 | |
| Adaptive Biotechnologies Corporation | $25.26 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.91 | 2021 | |
| Amgen INC. | $19.49 | 2023 | Nplate, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2019 | |
| Servier Pharmaceuticals LLC | $15.20 | 2022 | |
| Immunocore Limited | $15.19 | 2025 | Kimmtrak |
| Janssen Biotech, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajini Manjunath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.